Compare Natera Inc. Common Stock (NTRA) vs Ulta Beauty Inc (ULTA) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Natera Inc. Common Stock vs Ulta Beauty Inc — how do they compare? Natera Inc. Common Stock trades at $393.27 (market cap $57.03B), while Ulta Beauty Inc trades at $595.03 (market cap $24.76B). The key difference: Natera Inc. Common Stock is far larger — about 2.3× Ulta Beauty Inc's market cap, and Natera Inc. Common Stock is trading nearer its 52-week high, Ulta Beauty Inc nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Natera Inc. Common Stock for 0 Days and Ulta Beauty Inc for 92 Days on average.
| NTRA | ULTA | |
|---|---|---|
Market Cap | $57.03B | $24.76B |
Volume | 1,131,157 | 507,422 |
Sector | Health | Consumer Cyclical |
52-Week High | $425.64 | $706.82 |
52-Week Low | $179.42 | $450.75 |
Typical Hold Time | 0 Days | 92 Days |
Enterprise Value | $56.18B | $27.07B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
NTRA trades at $395.66, down 0.53% today but remains near recent highs. The stock shows mixed technical signals with neutral momentum indicators. Fundamentally, the company demonstrates strong revenue growth ($2.31B in 2025, projected $2.7B in 2026) but continues to operate at a net loss (-$208M in 2025). Recent positive developments include FDA Breakthrough Device designation for its multi-cancer detection assay and regulatory approval in Japan for Signatera.
NTRA presents a growth story with significant analyst support (89% buy ratings) but carries execution risks. The stock trades at premium valuations (P/S 20.48) while still unprofitable. Key catalysts include clinical trial progress and international expansion, though investors face risks from ongoing losses and competitive pressures in precision medicine.
ULTA stock trades at $592.42, up 4.4% on the day, reflecting strong momentum after recent earnings beats and raised guidance. The technical outlook is bullish, with the current price near resistance at $589. Fundamentally, the company shows robust profitability with a 9.34% net margin and 46.12% ROE, though revenue growth has moderated. Analyst sentiment remains positive with a consensus price target of $624.93 and 60% buy ratings, supported by e-commerce strength and expansion into wellness categories.
The outlook for ULTA is favorable, driven by e-commerce acceleration and strategic initiatives, but risks include margin pressure from promotions and flat store traffic. Valuation at a P/E of 21.09 appears reasonable given growth prospects, yet execution on new categories and macroeconomic sensitivity to consumer spending are key watchpoints for sustained upside.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About Natera Inc. Common Stock
Natera, Inc. develops and provides cell-free DNA-based genetic testing across women's health, oncology, organ health, and rare disease, with flagship products including Panorama for noninvasive prenatal screening and Signatera for cancer recurrence monitoring.
Read more on NTRA →About Ulta Beauty Inc
With more than 1,300 stores and a partnership with Target, Ulta Beauty is the largest specialized beauty retailer in the U.S. The firm offers makeup (43% of 2021 sales), fragrances, skin care, and hair care products (20% of 2021 sales), and bath and body items. Ulta offers private-label products and merchandise from more than 500 vendors. It also offers salon services, including hair, makeup, skin, and brow services, in all stores. Most Ulta stores are approximately 10,000 square feet and are in suburban strip centers. Ulta was founded in 1990 and is based in Bolingbrook, Illinois.
Read more on ULTA →
